201 related articles for article (PubMed ID: 26376779)
1. Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone.
Mendes D; Alves C; Batel-Marques F
Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1259-70. PubMed ID: 26376779
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.
Starner CI; Schafer JA; Heaton AH; Gleason PP
J Manag Care Pharm; 2008; 14(6):523-31. PubMed ID: 18693776
[TBL] [Abstract][Full Text] [Related]
3. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.
Loke YK; Kwok CS; Singh S
BMJ; 2011 Mar; 342():d1309. PubMed ID: 21415101
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
Dahabreh IJ; Economopoulos K
Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.
Nissen SE; Wolski K
Arch Intern Med; 2010 Jul; 170(14):1191-1201. PubMed ID: 20656674
[TBL] [Abstract][Full Text] [Related]
6. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
[TBL] [Abstract][Full Text] [Related]
7. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.
Singh S; Loke YK; Furberg CD
JAMA; 2007 Sep; 298(10):1189-95. PubMed ID: 17848653
[TBL] [Abstract][Full Text] [Related]
8. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.
Graham DJ; Ouellet-Hellstrom R; MaCurdy TE; Ali F; Sholley C; Worrall C; Kelman JA
JAMA; 2010 Jul; 304(4):411-8. PubMed ID: 20584880
[TBL] [Abstract][Full Text] [Related]
9. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
10. Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Bundhun PK; Janoo G; Teeluck AR; Huang F
BMC Pharmacol Toxicol; 2017 Oct; 18(1):66. PubMed ID: 29058622
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.
Nagajothi N; Adigopula S; Balamuthusamy S; Velazquez-Cecena JL; Raghunathan K; Khraisat A; Singh S; Molnar J; Khosla S; Benatar D
Am J Ther; 2008; 15(6):506-11. PubMed ID: 19127132
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis.
Norris SL; Carson S; Roberts C
Curr Diabetes Rev; 2007 May; 3(2):127-40. PubMed ID: 18220664
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
Lincoff AM; Wolski K; Nicholls SJ; Nissen SE
JAMA; 2007 Sep; 298(10):1180-8. PubMed ID: 17848652
[TBL] [Abstract][Full Text] [Related]
14. The cardiovascular safety of rosiglitazone.
Ajjan RA; Grant PJ
Expert Opin Drug Saf; 2008 Jul; 7(4):367-76. PubMed ID: 18613801
[TBL] [Abstract][Full Text] [Related]
15. Case series of liver failure associated with rosiglitazone and pioglitazone.
Floyd JS; Barbehenn E; Lurie P; Wolfe SM
Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1238-43. PubMed ID: 19623674
[TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone, myocardial ischemic risk, and recent regulatory actions.
Bourg CA; Phillips BB
Ann Pharmacother; 2012 Feb; 46(2):282-9. PubMed ID: 22298606
[TBL] [Abstract][Full Text] [Related]
17. Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD).
Bilik D; McEwen LN; Brown MB; Selby JV; Karter AJ; Marrero DG; Hsiao VC; Tseng CW; Mangione CM; Lasser NL; Crosson JC; Herman WH
Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):715-21. PubMed ID: 20583206
[TBL] [Abstract][Full Text] [Related]
18. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis.
Liao HW; Saver JL; Wu YL; Chen TH; Lee M; Ovbiagele B
BMJ Open; 2017 Jan; 7(1):e013927. PubMed ID: 28057658
[TBL] [Abstract][Full Text] [Related]
20. Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes?
Stone JC; Furuya-Kanamori L; Barendregt JJ; Doi SA
Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):223-7. PubMed ID: 25515780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]